Quantcast
Last updated on April 16, 2014 at 12:29 EDT

Latest American College of Rheumatology Stories

2010-04-27 14:18:32

A researcher from the University of Granada has designed a reliable method that "“combined with the diagnostic criteria of the American College of Rheumatology"“ helps to diagnose fibromyalgia on the basis of patients' walk parameters, i.e. their gait. Some of the altered parameters in this type of patient are: walk speed, step length, sole pressure on the ground, time on each foot, time on both feet, and step length. Thus, as it can be drawn from the research conducted at the...

2009-10-18 08:20:50

Research presented at the 2009 American College of Rheumatology meeting finds program initiates lifestyle changes According to a new study by Hospital for Special Surgery investigators presented at the American College of Rheumatology meeting on October 21 in Philadelphia, most lupus patients are not aware that their condition puts them at a higher risk for cardiovascular disease and a counseling program is a valuable way to promote education and lifestyle change. "Lupus patients are battling...

2009-08-19 06:25:00

JAMESBURG, N.J., Aug. 19 /PRNewswire/ -- Phytomedics Inc. today announced the publication of the results of a 6 month, Phase 2b clinical trial with an extract of Tripterygium wilfordii Hook F (TwHF) to be developed as PMI-001, in patients with rheumatoid arthritis, in the August 18, 2009 issue of the Annals of Internal Medicine. In an article entitled "Comparison of Tripterygium wilfordii Hook F versus Sulfasalazine in the Treatment of Rheumatoid," the TwHF extract or thundergod vine was...

2009-04-03 11:38:00

DXA Task Force Urges Congress to Pass Bill to Protect Patient Access WASHINGTON, April 3 /PRNewswire-USNewswire/ -- In an effort to protect patient access to osteoporosis testing and reduce the physical and economic burden of osteoporosis for millions of Americans, Congress introduced the "Medicare Fracture Prevention and Osteoporosis Testing Act of 2009," (S. 769 and H.R. 1894). Senators Blanche Lincoln (D-AR) and Olympia Snowe (R-ME) introduced the Senate version and Representatives...

2008-10-28 00:00:08

Bristol-Myers Squibb Company (NYSE: BMY) today announced at the American College of Rheumatology (ACR) Annual Scientific Meeting in San Francisco results from a 10-month study which showed that ORENCIA(R) (abatacept), compared to placebo, significantly improved multiple aspects of health-related quality of life (HRQoL): physical and psychosocial well being, pain and sleep quality in juvenile idiopathic arthritis (JIA) patients between the ages 6 and 17 years. These improvements with ORENCIA...

2008-10-27 18:00:10

Bristol-Myers Squibb Company (NYSE: BMY) today announced results from a Phase IIIb study in adult patients with early moderate-to-severe erosive rheumatoid arthritis (RA) who had never received previous methotrexate (MTX) treatment. This study showed that ORENCIA(R) (abatacept) in combination with MTX had significantly more patients achieve a Disease Activity Score 28 using C-reactive protein (DAS28 (CRP))-defined remission, compared with MTX plus placebo (PBO) (41.4 percent versus 23.3...

2008-10-27 09:00:12

SAN FRANCISCO, Oct. 27 /PRNewswire/ -- More than half of patients receiving every four week subcutaneous injections of golimumab (CNTO 148) 50 mg and 100 mg, an investigational therapy, experienced sustained improvements in the joint and skin symptoms of active psoriatic arthritis through six months with results sustained through one year. Golimumab-treated patients also experienced improvements in health-related quality of life (HRQOL) in the placebo-controlled portion of the study...

2008-10-26 19:01:19

Incyte Corporation (Nasdaq:INCY) announced today the presentation of clinical results from a 28-day Phase IIa trial of INCB18424, its orally available janus kinase (JAK) inhibitor, in patients with rheumatoid arthritis (RA). Results from the 50-patient placebo-controlled trial demonstrated that three of the four doses of INCB18424 evaluated (15 mg BID, 25 mg BID and 50 mg QD) produced impressive clinical benefits and all of the doses were well tolerated. American College of Rheumatology...

2008-10-25 21:00:11

NUTLEY, N.J., Oct. 25 /PRNewswire/ -- One-year data from a two-year Phase III study demonstrated that ACTEMRA(R) (tocilizumab) significantly inhibited the progression of structural joint damage in patients with rheumatoid arthritis (RA). Late-breaking results from the LITHE study will be featured as an oral presentation during the American College of Rheumatology (ACR) Annual Scientific Meeting (October 24-28) in San Francisco. Fourteen additional abstracts, which evaluate ACTEMRA, a novel...

2008-10-25 21:00:11

NUTLEY, N.J., Oct. 25 /PRNewswire/ -- Data from two Phase III studies showed that patients who suffer from the debilitating and painful effects of rheumatoid arthritis (RA) achieved significant improvements in signs and symptoms when treated with ACTEMRA(R) (tocilizumab) alone or in combination with methotrexate compared with methotrexate alone. The final results of both studies will be presented as oral presentations, along with 13 other abstracts which evaluate ACTEMRA in patients with...